NasdaqGS:NUVLBiotechs
Guardant Diagnostic Alliance Could Be A Game Changer For Nuvalent’s Targeted Oncology Strategy (NUVL)
In April 2026, Guardant Health announced a multi-year collaboration with Nuvalent to use its Guardant Infinity platform’s tissue and liquid biopsy tests in supporting Nuvalent’s global oncology trials and potential commercialization efforts.
This alliance highlights how pairing Nuvalent’s kinase-targeted cancer therapies with Guardant’s precision diagnostics could tighten patient selection, streamline regulatory pathways, and strengthen future companion diagnostic strategies.
Next, we’ll...